The New York Times once called John Lamattina, then Pfizer head of R&D, “Dr. Optimistic.” He’s not so optimistic now.
US plans to block federal funding for children’s gender-affirming care, sparking concerns from medical experts and advocacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback